Medically reviewed by Larysa Grevtsova, MD

Semaglutide vs Tirzepatide: What’s the Difference?

The Core Difference: One Hormone Target vs Two

Semaglutide — sold as Ozempic (diabetes) and Wegovy (weight management) — is a single-receptor agonist. It mimics GLP-1 only.

Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight management) — is a dual-receptor agonist. It mimics both GLP-1 and a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide).

GIP works alongside GLP-1 to regulate insulin secretion and fat metabolism, but through a partially different pathway. By activating both receptors at once, tirzepatide produces a broader combined effect on appetite suppression, insulin sensitivity, and fat breakdown than targeting GLP-1 alone.

Which One Produces More Weight Loss?

Across separate large-scale trials, tirzepatide has generally shown somewhat greater average weight loss than semaglutide, with participants on the highest tirzepatide doses losing more total body weight on average than those on the highest semaglutide doses over comparable trial periods. That said, “average” is doing a lot of work in that sentence — individual response varies widely based on starting weight, dose, adherence, and metabolic factors, and plenty of people respond extremely well to semaglutide specifically.

Neither medication has been tested head-to-head against the other in a single trial designed to directly compare them at matched doses, so most of what we know comes from comparing separate trial results rather than one true side-by-side study.

Side Effect Profiles

Both medications share a similar side effect category — mostly gastrointestinal — because both slow gastric emptying as part of how they work.

• Nausea, constipation, diarrhea, and vomiting are common to both, especially during dose escalation.
• Some patients report that tirzepatide’s dual mechanism produces a slightly different side effect pattern for them individually, though large-scale comparative data on this specific point is limited.
• Both medications carry the same general warnings around thyroid tumors in animal studies, pancreatitis risk, and gallbladder issues, and both require the same kind of medical screening before a prescription is issued.

Dosing and Administration

Both are administered as subcutaneous injections, typically once per week, usually starting at a low dose that’s gradually increased over several weeks or months to reduce side effects. Neither is a daily pill in its original form (oral semaglutide exists as a separate medication, Rybelsus, primarily for diabetes management — we cover oral GLP-1 options separately in our pills-vs-injections guide).

Cost and Availability Differences

Because tirzepatide is a newer and more complex molecule to manufacture, it has generally carried a higher list price than semaglutide, and insurance coverage rules differ between the two — a plan that covers Wegovy doesn’t automatically cover Zepbound, and vice versa. Compounded versions of both exist through telehealth providers, though compounded tirzepatide has faced more supply and regulatory scrutiny at different points due to manufacturing complexity. We break down current pricing and insurance patterns in our dedicated cost guide and insurance coverage guide.

Which Should You Choose?

There isn’t a universal answer — the right choice depends on your health history, what your insurance actually covers, how your body responds to each medication, and what your prescriber recommends after reviewing your case. Some people try semaglutide first because it has a longer track record, then switch to tirzepatide if results plateau; others start with tirzepatide from the outset based on their doctor’s guidance. This is a decision to make with a licensed medical provider who has reviewed your specific health profile, not one to make based on marketing claims from either manufacturer.

If you’re comparing telehealth providers to figure out which medications they prescribe and at what cost, our comparison table lays out the differences between the major programs side by side.